Evaluation of BI 3000202 Pharmacokinetics and Tolerability in Healthy Male Volunteers Under Fed and Fasted Conditions

The primary objective of this study is to evaluate the **tolerability** of different doses of BI 3000202 in healthy male volunteers. This is clinically relevant as it helps determine the safety profile of the investigational product, which is crucial for its potential future use in therapeutic settings. Additionally, the study aims to assess how food intake influences the pharmacokinetics of BI 3000202, providing insights into optimal administration conditions. No secondary objectives are specified for this trial.

The clinical trial involves a study population of **healthy volunteers**. The participants are exclusively male, with an age range that corresponds to the category code "3," which typically includes young adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population, as well as any specific lifestyle considerations such as diet or physical activity, have not been disclosed. The trial does not include female subjects, and no significant inclusion or exclusion criteria have been specified by the sponsor.

The clinical trial is designed as a **Phase 1** study involving healthy male volunteers to evaluate the tolerability of varying doses of BI 3000202 and to assess the impact of food on its pharmacokinetics. The trial employs a **randomized**, **double-blind**, and **controlled** methodology to ensure the reliability and validity of the results. The estimated duration of the trial spans from July 25, 2023, to November 15, 2023, encompassing both the recruitment and study phases.

Participants will undergo a sequence of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for confirming the health status of the volunteers and ensuring they meet the study's inclusion criteria. Following the initial screening, participants will attend multiple follow-up visits, during which they will receive the investigational product and undergo various assessments to monitor their response to the treatment and any potential side effects. The trial will conclude with an end-of-study visit, where final evaluations are conducted to gather comprehensive data on the study's primary and secondary endpoints.

The expected length of participant involvement is approximately four months, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to adhere to the study protocol, or withdraw consent. The trial's design and procedures are structured to maintain the highest ethical standards and ensure the safety and well-being of all participants throughout the study period.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating its primary focus on safety and dosage, with preliminary efficacy assessments. The trial is scheduled to commence recruitment on July 25, 2023, and is estimated to conclude by November 15, 2023. Although specific efficacy endpoints are not detailed, typical Phase 1 trials may involve the collection of preliminary data on efficacy parameters such as symptom improvement or biomarker changes. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales or laboratory tests. The trial's design and execution will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments.